What Vitamin K2 MK-7 Does

Vitamin K2 MK-7 is a form of vitamin K that your body uses to set up proteins involved in bone mineralization and blood vessel health. Unlike K1 (found in leafy greens), MK-7 is produced by bacteria in fermented foods and in your gut, and it stays in your bloodstream longer—up to three days compared to K1's few hours. This longer residence time is why researchers have studied it separately from other K vitamins.

The mechanism is specific: MK-7 activates two main proteins. The first is osteocalcin, which binds calcium into bone mineral. The second is matrix Gla protein, which prevents calcium from depositing in soft tissues like arteries. In theory, this dual action could support bone density while reducing arterial stiffness. Whether this happens in practice depends on dose, duration, and individual factors like baseline vitamin K status and calcium intake.

Key Takeaways

  • MK-7 activates bone and vascular proteins that require vitamin K, but human evidence for bone density gains is limited to a few trials of 12 months or longer.
  • Most human studies showing benefit used doses of 90 to 180 micrograms daily, which is higher than typical food sources provide.
  • Animal and cell studies suggest MK-7 may reduce arterial calcification, but human trials testing this directly are still scarce.
  • MK-7 does not replace calcium or vitamin D; all three are needed for bone health, and deficiency in any one limits the others' effect.
  • People taking warfarin or other vitamin K antagonists should not increase MK-7 intake without medical guidance, as it can reduce drug effectiveness.

Bone Density: What Human Trials Show

The strongest evidence for MK-7 comes from bone studies in postmenopausal women, the group at highest risk for osteoporosis. A 2013 trial published in Osteoporosis International gave 244 women either 180 micrograms of MK-7 or placebo daily for three years. The MK-7 group showed a small slowing of bone loss in the spine and hip compared to placebo, but the difference was modest—roughly 1 to 2 percent better retention. Bone density did not increase; loss straightforward slowed.

A smaller 2015 Japanese trial of 60 women found similar results: 45 micrograms of MK-7 daily for two years slowed spinal bone loss compared to placebo. However, neither trial showed dramatic reversal of bone loss or prevention of fractures. The studies were long enough to detect real changes, but the effect size was small, and neither included a comparison to established osteoporosis drugs like bisphosphonates.

In younger, healthy adults, the evidence is thinner. Most studies in this group are short (under 12 weeks) and measure only biochemical markers—whether osteocalcin becomes more activated—rather than actual bone density. set up of the protein is necessary but not sufficient to prove bone strength improves.

Arterial Calcification and Cardiovascular Health

Animal studies and cell cultures show that MK-7 can reduce calcium deposition in artery walls, at least in controlled conditions. The mechanism makes sense: matrix Gla protein, when activated by MK-7, acts as a brake on soft-tissue calcification. In rats fed high-calcium diets, MK-7 supplementation reduced arterial stiffness compared to controls.

Human evidence is much weaker. One observational study of 564 Dutch adults found that higher dietary vitamin K2 intake (from all sources, not just MK-7) was associated with less arterial calcification on CT scans. However, observational studies cannot prove cause and effect—people who eat more fermented foods may also exercise more or have other healthy habits. No large randomized trial has yet tested whether MK-7 supplementation actually reduces heart attacks or strokes.

A 2015 trial in 244 postmenopausal women measured arterial stiffness alongside bone density. MK-7 did not significantly improve arterial stiffness compared to placebo over three years, though the study was not designed to detect small improvements in this outcome.

Food Sources Versus Supplements

MK-7 is produced by bacteria during fermentation, so it is found in natto (fermented soybeans), some cheeses, sauerkraut, and other fermented foods. A single serving of natto contains 100 to 400 micrograms of MK-7—far more than most other foods. A typical serving of aged cheese contains 10 to 35 micrograms. Sauerkraut and other fermented vegetables contain smaller amounts, usually under 10 micrograms per serving.

Most people in Western diets consume less than 10 micrograms of MK-7 daily from food. The trials showing bone benefits used 45 to 180 micrograms daily, which is difficult to reach through food alone unless you eat natto regularly. This gap is why researchers have studied supplementation: to test whether doses higher than typical intake produce measurable health changes.

If you eat natto or aged cheese regularly, your MK-7 intake is likely adequate for the protein set up that occurs in those trials. If you do not, a supplement may bring you to the dose tested in research, though the clinical significance of that dose remains modest.

How MK-7 Interacts With Other Nutrients

Vitamin K2 MK-7 does not work in isolation. Osteocalcin and matrix Gla protein require not only vitamin K but also adequate calcium and vitamin D. If calcium intake is very low, activating these proteins will not prevent bone loss. If vitamin D status is poor, calcium absorption is impaired regardless of how much K2 is present. Research on bone health shows that the effect of any single nutrient is limited when others are deficient.

One small trial gave postmenopausal women MK-7 plus vitamin D and calcium, and found better bone density outcomes than MK-7 alone. This suggests that the combination matters more than any single component. If you are considering MK-7 supplementation for bone health, checking your vitamin D level and ensuring adequate calcium intake (roughly 1,000 to 1,200 mg daily depending on age) is more important than the MK-7 dose.

Safety and Drug Interactions

MK-7 is well tolerated in the doses tested in human trials (up to 180 micrograms daily). No serious adverse events have been reported in the published literature. However, one critical interaction exists: if you take warfarin or other vitamin K antagonists (anticoagulants used to prevent blood clots), increasing MK-7 intake can reduce the drug's effectiveness by activating clotting factors that the drug is meant to suppress.

This does not mean you cannot take MK-7 if you are on warfarin, but it means the dose must be consistent and monitored. Your doctor can adjust your warfarin dose if needed, but sudden changes in MK-7 intake—either from supplements or from eating much more natto—can destabilize your anticoagulation. If you are on warfarin and considering MK-7 supplementation, discuss it with your prescribing physician first.

People on newer anticoagulants like apixaban (Eliquat) or rivaroxaban (Xarelto) have less interaction with vitamin K, but the same principle applies: consistency matters more than avoidance.

What Remains Unclear

The gap between what we know and what we do not know is substantial. We know MK-7 activates the right proteins in bone and blood vessels. We know that in postmenopausal women, high-dose MK-7 slows bone loss modestly. We do not know whether this slowing translates to fewer fractures, because no trial has run long enough or been large enough to measure fracture rates. We do not know whether MK-7 prevents heart disease in humans, despite plausible mechanisms and animal evidence.

We also do not know the optimal dose. The trials used 45 to 180 micrograms daily, but whether 30 micrograms is sufficient, or whether 200 micrograms is better, has not been tested head-to-head. We do not know whether MK-7 is more effective than MK-4 (another form of K2) or K1 for bone health, because direct comparison trials are rare.

These gaps do not mean MK-7 is ineffective—they mean the evidence is preliminary and the effect size is small. If you are considering it, the realistic expectation is modest slowing of bone loss in the context of adequate calcium and vitamin D, not reversal of osteoporosis or prevention of heart disease.

Frequently Asked Questions

Is MK-7 better than regular vitamin K1 for bones?

MK-7 stays in the bloodstream longer and activates bone proteins more persistently, which is why researchers study it separately. However, no trial has directly compared MK-7 to K1 for bone density outcomes. Both forms set up osteocalcin; MK-7 may do so more efficiently, but the clinical difference is unknown.

Can I get enough MK-7 from food?

If you eat natto regularly, yes—one serving provides more MK-7 than the doses used in trials. If you eat aged cheese or fermented vegetables occasionally, you likely get under 20 micrograms daily. The trials showing bone benefits used 45 to 180 micrograms, so supplementation may be needed to reach those doses.

Will MK-7 prevent osteoporosis?

The evidence shows it slows bone loss in postmenopausal women, not prevents it. No trial has shown that MK-7 alone prevents fractures. It works best alongside adequate calcium and vitamin D, and is not a substitute for exercise or established osteoporosis treatments if you have already been diagnosed.

How long does it take to see results from MK-7?

Bone density changes take months to years to measure. The trials ran for 2 to 3 years before detecting differences. Biochemical markers like osteocalcin set up can shift within weeks, but these do not directly tell you whether bone strength is improving.

Can I take MK-7 if I am on blood thinners?

Warfarin and other vitamin K antagonists interact with MK-7 because it activates clotting factors. You can take both, but your warfarin dose may need adjustment and your INR (blood clotting measure) must be monitored. Discuss any MK-7 supplementation with your doctor before starting. Newer anticoagulants like apixaban have less interaction but still require consistency.